Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Liver International · 2025-08 · 45 (8)
DOI: 10.1111/liv.70231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 28.07.2025. Verfasst von Marco Castelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medicine C, University of Verona and Hospital Trust of Verona (Azienda Ospedaliera Universtaria AOUI), Verona, Italy. Hauptthemen laut MEDLINE: Platelet Activation, Liver Cirrhosis, Blood Platelets, Fatty Liver. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease, often progressing to fibrosis and up to cirrhosis. Platelet activation plays a potential role in MASLD progression, but its functional profile across disease stages remains unclear. This study aimed to characterise the platelet functional profile and phenotype in patients with MASLD ≤ F2 and F3–F4 fibrosis compared to healthy controls.
Methods
We analysed biomarkers of in vivo platelet activation, including urinary 11‐dehydro‐thromboxane B2 (11‐dh‐TXB 2 ) and plasma soluble P‐selectin. Platelet phenotype was assessed via microfluidic assays and flow cytometry, evaluating adhesion and fibrinogen receptor activation and Annexin V. Patients were stratified according to liver stiffness measurement (LSM) into low fibrosis MASLD (≤ F2) and advanced fibrosis/cirrhosis (F3–F4).
Results
Urinary 11‐dh‐TXB 2 was comparable between control and the ≤ F2 patients (median difference: 7365 ng/g creatinine, 95% CI: 5257–8764); higher values were observed in F3–F4 patients, with levels significantly elevated compared to controls (6931 ng/g creatinine, 95% CI: 5290–8363). Plasma soluble P‐selectin followed a similar trend. Platelet phenotype MASLD ≤ F2 patients exhibited increased adhesiveness (median difference: 289.8 a.u., 95% CI: 195.8–458.2) and displayed procoagulant activity through binding of Annexin V, whereas F3–F4 patients showed increased adhesiveness (median difference: 361.1 a.u., 95% CI: 163.4–530.4) and reduced fibrinogen receptor activation.
Conclusions
Platelet activation markers correlate with fibrosis severity, highlighting their potential role in disease progression. MASLD ≤ F2 is associated with increased platelet adhesiveness, whereas F3–F4 is characterised by impaired platelet reactivity despite high activation markers. These findings support the involvement of platelets in MASLD fibrosis progression and suggest their potential as biomarkers or therapeutic targets. Impact and Implications This study provides a robust scientific rationale for further exploring platelet dynamics as both biomarkers and potential therapeutic targets in MASLD, by demonstrating distinct platelet functional profiles between early (MASLD ≤ F2) and advanced fibrosis (F3–F4). The observed increase in platelet adhesiveness and procoagulant activity in early MASLD, contrasted with a reduced reactivity in advanced stages despite elevated activation markers, is critical for clinicians and researchers aiming to refine risk stratification and optimise treatment strategies. These findings could be practically applied by guiding physicians in monitoring platelet activation markers to identify patients at higher risk of fibrosis progression and by informing the development of targeted antiplatelet interventions. However, given the cross‐sectional design of the study and its inherent methodological limitations, these implications warrant cautious interpretation and further validation through longitudinal research. Trial Registration 1612CESC
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medicine C, University of Verona and Hospital Trust of Verona (Azienda Ospedaliera Universtaria AOUI), Verona, Italy.
- Liver Unit, Department Medicine, University of Verona, Verona, Italy.
ORCID-Profile: Marco Castelli, Andrea Dalbeni
Zitieren
APA
Castelli, M., Zoncapè, M., Meneguzzi, A., Mantovani, A., Sacerdoti, D., Minuz, P., & Dalbeni, A. (2025). Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International, 45(8). https://doi.org/10.1111/liv.70231
Vancouver
Castelli M, Zoncapè M, Meneguzzi A, Mantovani A, Sacerdoti D, Minuz P, et al. Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2025;45(8). doi:10.1111/liv.70231
BibTeX
@article{Castelli2025,
author = {Castelli, Marco and Zoncapè, Mirko and Meneguzzi, Alessandra and Mantovani, Anna and Sacerdoti, David and Minuz, Pietro and Dalbeni, Andrea},
title = {Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Liver International},
year = {2025},
volume = {45},
number = {8},
doi = {10.1111/liv.70231}
}
EUVIMED